Valiant Laboratories Ltd

Dematerialisation status

• Reg 74(5) not applicable; all securities dematerialised; no requests received during quarter ended 30 Sep 2026.

Valiant Laboratories Limited — Trading Window closed from October 01, 2026 until the expiry of 48 hours after the declaration of Financial Results for the quarter and half year ended September 30, 2026

AGM Details

• AGM held on 28 September 2026 at 11:30 AM via Video Conference/AVM.
• Record date for voting: 21 September 2026.

Key Resolutions

• Adopt standalone financial statements and reports.
• Appoint/re-appoint directors, including independent, for terms.
• Appoint statutory auditors and fix their remuneration.
• Approve material related party transactions.
• Approve remuneration for directors.
• Approve shifting of registered office to another state.

Voting Results

• All resolutions passed; no significant dissent reported.

Director Changes

• Multiple director appointments/re-appointments approved.

Auditor Appointments

• Statutory auditors appointed; remuneration fixed.

Material Related Party Transactions

• Approved material related party transactions with specified entities.

Other Material Approvals

• Shifting of registered office outside the current state.

AGM Details

• Date/time: Sep 28, 2026, 11:30 IST; mode: VC/OAVM.
• Attendance: 38 members via VC/OAVM; e-voting available pre and during AGM.

Key Resolutions

• Item 1 (Ord): Adopt audited standalone and consolidated financials for FY ended Mar 31, 2026.
• Item 2 (Ord): Appoint Sandeep Gupta as director (re-appointment).
• Item 3 (Ord): Ratify remuneration to Cost Auditors for FY 2026-27.
• Item 4 (Ord): Approve material related party transactions with Valiant Organics Ltd.
• Item 5 (Ord): Approve RPT with Aarti Pharmalabs Ltd.
• Item 6 (Ord): Approve RPT between VASPL and Valiant Organics Ltd.
• Item 7 (Ord): Approve RPT between VASPL and Aarti Pharmalabs Ltd.
• Item 8 (Ord): Approve RPT between VASPL and Alchemie SpecialityChemicals Pvt Ltd.
• Item 9 (Special): Re-appoint Santosh Vora as MD for 5 years; fix remuneration.
• Item 10 (Special): Re-appoint Sonal Vira as Independent Director for second term.
• Item 11 (Special): Revise remuneration of Paresh Shah, WTD & CFO.
• Item 12 (Special): Continue Shantilal Vora as Non-Executive Non-Independent Director after 75.
• Item 13 (Special): Pay remuneration by way of commission to Sandeep Gupta.
• Item 14 (Special): Pay remuneration by way of commission to Mulesh Savla.
• Item 15 (Special): Pay remuneration by way of commission to Sonal Vira.
• Item 16 (Special): Pay remuneration by way of commission to Ashok Chheda.
• Item 17 (Special): Pay remuneration by way of commission to Ashok Chheda.
• Item 18 (Special): Shift registered office outside Maharashtra.

Voting Results

• All items transacted; voting outcomes not disclosed in filing.

Director Changes

• MD re-appointment: Santosh Vora for five years.
• Independent Director re-appointment: Sonal Vira for second term.
• Continuation: Shantilal Vora to remain Non-Executive Non-Independent Director after 75.

Auditor Appointments

• Statutory auditor attended; no appointment/tenure changes disclosed.

Material Related Party Transactions

• RPT with Valiant Organics Ltd.
• RPT with Aarti Pharmalabs Ltd.
• RPT between VASPL and Valiant Organics Ltd.
• RPT between VASPL and Aarti Pharmalabs Ltd.
• RPT between VASPL and Alchemie SpecialityChemicals Pvt Ltd.

Other Material Approvals

• Remuneration-related approvals for directors (Items 11-17).
• Shifting of registered office outside Maharashtra (Item 18).

Target and business

• AMPYR Renewable Energy Resources Twelve A Private Limited, an Indian solar power developer and generator.
• Subsidiary of AMPYR India Asset Holdings Two Pte. Ltd., Singapore.
• Solar park project at Mhasale, Sakri, Dhule, Maharashtra.

Size and financials

• Net worth ₹9.99 crore; turnover ₹23.26 crore as of 31 March 2026.

Transaction characteristics

• Acquisition is not a related party transaction; no promoter interest.
• Cash consideration up to ₹70 lakh; shares to be acquired from existing shareholders.
• Proposed holding up to 1.01% equity and up to 3.60% CCD.

Regulatory

• No regulatory approvals beyond corporate approvals under the Companies Act 2013.

Rationale and timing

• To participate in group captive arrangement to procure solar power for Tarapur plant.
• Transaction may be in one or more tranches; completion within 12 months from approval.
• No change in control of the target.

Background of target

• Incorporated 1 November 2023; plant commenced operations May 27, 2025.
• Turnover FY2025-26 ₹23.26 crore; FY24-25 NIL; FY23-24 NIL.

Rating details

• Instrument: Bank loan facilities; INR 560 million limit.
• Rating: IND BBB/Stable (long-term) and IND A2 (short-term).
• Outlook: Stable for the long-term rating.
• Rating agency: India Ratings and Research (Ind-Ra).
• Rationale: Not disclosed in chunk; references press release.

AGM notice and email-registration update

• Letters sent to members without registered emails as of Aug 28, 2026.
• AGM 5th scheduled for Sep 28, 2026 at 11:30 IST via VC/OAVM.
• Notice and Annual Report FY2025-26 accessible via web link and company site.
• Web link provided: https://www.valiantlabs.in/assets/images/investors/annual-report-2026.pdf; path on site.
• Also available on BSE/NSE websites; AGM Notice on NSDL evoting.
• Physical shareholders to MUFG Intime with ISR forms; email investor.helpdesk@in.mpms.mufg.com.
• KYC forms downloadable from the company's website.